Sign In
Get Clay Free →

Suggestions

    Jason Geipel

    Director of Strategy at Biolumina

    Professional Background

    Jay Geipel is a highly experienced healthcare marketing professional who specializes in oncology, with a distinguished career spanning over 15 years. His extensive expertise encompasses both solid tumors and hematologic malignancies, encompassing core disease states such as Renal Cell Carcinoma (RCC), ER+/HER2- and HER2+ Breast Cancer (BC), Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Jay has a deep understanding of various classes and mechanisms of action (MoA) that are crucial in today's clinical landscape, including mTOR inhibitors, Selective Estrogen Receptor Degraders (SERD), JAK1/2 inhibitors, Histone Deacetylase inhibitors (HDAC), Cyclin-Dependent Kinase 4 and 6 (CDK4/6), as well as immune checkpoint inhibitors CTLA-4 and PD-L1.

    Throughout his career, Jay Geipel has demonstrated remarkable leadership skills, successfully leading both US and global product launches across multiple therapeutic categories, particularly in oncology, cardiovascular health, and antibiotic sectors. His client partnership experience is extensive, working collaboratively with major pharmaceutical companies such as Pfizer, AstraZeneca, Novartis, Janssen, SeaGen, Roche, and Exelixis. These partnerships have involved notable products, where he played a pivotal role in the launch and promotion of various innovative therapies, including IBRANCE, IMFINZI, TAGRISSO, and JAKAVI, among others.

    In addition to his remarkable client collaboration, Jay has impressive brand-level experience that spans the entire lifecycle of drug development, from pre-launch and clinical development phases to launch and late-stage life-cycle management. His achievements extend beyond oncology; he has developed significant portfolio branding strategies in both oncology (Pfizer's RCC and AstraZeneca's NSCLC) and antibiotics (Cubist/Merck: Infectious Disease). His career has included work across the US, global, and emerging markets, showcasing his adaptability and expertise within diverse healthcare systems.

    Jay currently serves as the Vice President and Account Director at Dudnyk, where he utilizes his wealth of knowledge and strategic insight to guide teams in delivering impactful marketing solutions within the healthcare sector. His commitment to ensuring that patients gain access to innovative treatments underlines his dedication to the field of healthcare marketing.

    Education and Achievements

    Jay's academic background complements his professional experience. Although specific details of his educational journey are not provided, it is likely that his training and education have anchored his vast knowledge in oncology and strategic marketing. His expertise in navigating complex healthcare markets has been refined through years of collaboration and leadership within reputable organizations, positioning him as a thought leader in oncology marketing.

    Jay's record of excellence in driving successful product launches is a testament to his strategic vision and ability to execute comprehensive marketing strategies. By adeptly working with cross-functional teams, he has consistently achieved milestones that contribute to improved patient outcomes and increased market access to essential therapies. His strong relationships with healthcare professionals and stakeholders underscore his effectiveness in developing client-centered approaches that resonate within the competitive pharmaceutical landscape.

    Achievements

    Jay Geipel's career is marked by numerous achievements that highlight his profound impact on the oncology market and beyond. His proven success in launching key oncology therapies reflects his deep understanding of the healthcare landscape and his ability to leverage partnerships effectively. Some prominent highlights of his recent career include:

    • Successfully executing the launch strategies for high-profile oncology products in collaboration with leading pharmaceutical clients, including but not limited to:
      • Pfizer: launching IBRANCE for HR-positive, HER2-negative breast cancer, MMS-2 for a key indication, and positioning TORISEL in renal cell carcinoma.
      • AstraZeneca: overseeing the introduction of IMFINZI for lung cancer treatment.
      • Novartis: driving the launch of JAKAVI for myelofibrosis.
    • Proven leadership in global launch initiatives that cemented his reputation as a trusted leader in the oncology space.
    • Effectively managing client partnerships that span various therapeutic areas—showcasing his versatility and commitment to excellence in marketing.
    • Bringing innovative antibiotics and oncology brands to market, demonstrating his ability to navigate complex regulatory environments and market challenges successfully.

    As a dedicated professional, Jay Geipel continues to be a significant contributor to the oncology marketing landscape, showcasing an unwavering commitment to patient access and advancing healthcare initiatives. His rich experience and strategic insights are assets that serve to benefit the organizations he partners with and the patients they ultimately help.

    Related Questions

    How did Jay Geipel develop his extensive expertise in oncology marketing and product launches?
    What specific strategies has Jay Geipel employed to ensure successful client partnerships in pharmaceuticals?
    How does Jay Geipel approach brand management for oncology products across various therapeutic areas?
    What factors contribute to Jay Geipel's success in both US and global marketing strategies within the healthcare sector?
    How has Jay Geipel's experience in hematologic malignancies shaped his overall approach to oncology marketing?
    J
    Add to my network

    Location

    Greater New York City Area